golimumab
janssen,merck
['axspa']
weinstein et al. go-back. another tnfi withdrawal study in nr-axspa. again showing it doesn't work. 12 months. only 34% of withdrawal group in remission vs 84% full dose and 68% reduced dose group. #acr22 abstr#0545 
Rheumatologist @stjamesdublin , Associate Professor @tcddublin , Acute Medicine, Vasculitis, ILD, Retired @Emeunet Executive Committee member, @rheum_covid CASC